In recent years,the potential role of mitochondrial dynamics imbalance in the pathogenesis of various psychiatric disorders has attracted growing attention.Mitochondria regulate energy metabolism,oxidative stress,apoptosis,and neuronal function through dynamic processes such as fission and fusion.Disruption of these processes may impair synaptic function and neural network stability.In schizophrenia,depression,bipolar disorder,Alzheimer disease,and autism spectrum disorders,studies have reported dysregulated expression of mitochondrial fission-related proteins DRP1 and FIS1,as well as fusion-related proteins MFN1,MFN2,and OPA1,accompanied by structural and functional mitochondrial impairments,neuronal apoptosis,and synaptic loss.Evidence from clinical studies,animal models,and cell experiments further supports that these mitochondrial dynamics abnormalities are closely associated with cognitive deficits,emotional disturbances,and neurodegenerative changes.Although mitochondrial dynamic dysfunction alone cannot fully explain the onset of psychiatric disorders,it may represent a potential biological mechanism that offers new insights into disease mechanisms and provide a theoretical basis for developing targeted intervention strategies.

In recent years,the potential role of mitochondrial dynamics imbalance in the pathogenesis of various psychiatric disorders has attracted growing attention.Mitochondria regulate energy metabolism,oxidative stress,apoptosis,and neuronal function through dynamic processes such as fission and fusion.Disruption of these processes may impair synaptic function and neural network stability.In schizophrenia,depression,bipolar disorder,Alzheimer disease,and autism spectrum disorders,studies have reported dysregulated expression of mitochondrial fission-related proteins DRP1 and FIS1,as well as fusion-related proteins MFN1,MFN2,and OPA1,accompanied by structural and functional mitochondrial impairments,neuronal apoptosis,and synaptic loss.Evidence from clinical studies,animal models,and cell experiments further supports that these mitochondrial dynamics abnormalities are closely associated with cognitive deficits,emotional disturbances,and neurodegenerative changes.Although mitochondrial dynamic dysfunction alone cannot fully explain the onset of psychiatric disorders,it may represent a potential biological mechanism that offers new insights into disease mechanisms and provide a theoretical basis for developing targeted intervention strategies.

The prevalence of depressive disorders in adolescents sharply increases, which seriously affects the mental health of adolescents. Anhedonia, as one of core symptoms of depressive disorder, is defined as almost daily and significant loss of interest and pleasure. Anhedonia has a strong correlation with suicide risk in patients with depressive disorder. It often indicates poor prognosis and psychosocial functioning. Anhedonia is reported in more than 50% of adolescents with depression. It presents differently in adolescents compared to adults. However, the measurement tools currently used are mainly designed for adults. Their suitability for adolescents is questionable. There is a lack of research on the identification, assessment, and intervention of anhedonia in adolescents. This review discusses the progress of research on the symptomatologic characteristics, assessment tools, and treatments for anhedonia in adolescent depression to provide references for psychiatric clinicians, psychotherapists, and researchers.

The prevalence of depressive disorders in adolescents sharply increases, which seriously affects the mental health of adolescents. Anhedonia, as one of core symptoms of depressive disorder, is defined as almost daily and significant loss of interest and pleasure. Anhedonia has a strong correlation with suicide risk in patients with depressive disorder. It often indicates poor prognosis and psychosocial functioning. Anhedonia is reported in more than 50% of adolescents with depression. It presents differently in adolescents compared to adults. However, the measurement tools currently used are mainly designed for adults. Their suitability for adolescents is questionable. There is a lack of research on the identification, assessment, and intervention of anhedonia in adolescents. This review discusses the progress of research on the symptomatologic characteristics, assessment tools, and treatments for anhedonia in adolescent depression to provide references for psychiatric clinicians, psychotherapists, and researchers.

Recently, the situation of the preventing and controlling of the novel coronavirus infection has changed. After patients with mental disorders are infected with the new coronavirus (hereinafter referred to as the new coronavirus), they will face the following problems: whether the drugs related to the new coronavirus infection can be used at the same time as the psychiatric drugs, and whether there will be pharmacokinetic or pharmacodynamic interactions between the medicines How to avoid the safety risks brought by drug interactions? Focusing on the above issues, this article puts forward some suggestions based on the summary of existing evidence, hoping to help front-line doctors.

Recently, the situation of the preventing and controlling of the novel coronavirus infection has changed. After patients with mental disorders are infected with the new coronavirus (hereinafter referred to as the new coronavirus), they will face the following problems: whether the drugs related to the new coronavirus infection can be used at the same time as the psychiatric drugs, and whether there will be pharmacokinetic or pharmacodynamic interactions between the medicines How to avoid the safety risks brought by drug interactions? Focusing on the above issues, this article puts forward some suggestions based on the summary of existing evidence, hoping to help front-line doctors.

Schizophrenia is a common chronic disabling mental disorder with complex etiology and pathological mechanism. Over the past 70 years, antipsychotics have primarily acted on D 2 receptors, with poor response to negative symptoms and cognitive impairment and more adverse effects, which have significantly affected patient compliance and functional recovery. Therefore, the development of new-targeted antipsychotic drugs is particularly urgent. SEP-363856 is a non-D 2-receptor-binding drug for the treatment of schizophrenia which is found by phenotypic screening strategies, and the pharmacological mechanism has not been fully elucidated. Preclinical data suggest that SEP-363856 may active Trace amine associated receptor 1 (TAAR1) and 5-HT 1A receptors, and the discovery of this drug shed light on new treatment options for schizophrenic. This review provides an introduction of the development of SEP-363856, including preclinical findings and the latest clinical trial data, to help readers understand this new antipsychotic drug.

Schizophrenia is a common chronic disabling mental disorder with complex etiology and pathological mechanism. Over the past 70 years, antipsychotics have primarily acted on D 2 receptors, with poor response to negative symptoms and cognitive impairment and more adverse effects, which have significantly affected patient compliance and functional recovery. Therefore, the development of new-targeted antipsychotic drugs is particularly urgent. SEP-363856 is a non-D 2-receptor-binding drug for the treatment of schizophrenia which is found by phenotypic screening strategies, and the pharmacological mechanism has not been fully elucidated. Preclinical data suggest that SEP-363856 may active Trace amine associated receptor 1 (TAAR1) and 5-HT 1A receptors, and the discovery of this drug shed light on new treatment options for schizophrenic. This review provides an introduction of the development of SEP-363856, including preclinical findings and the latest clinical trial data, to help readers understand this new antipsychotic drug.

Objective:To investigate the reliability and validity of the Chinese Version of Dimensional Anhedonia Rating Scale (DARS).Methods:136 subjects who were diagnosed with depressive disorder and 30 healthy controls were selected to complete the Chinese version of DARS, Hamilton Depression Scale (HAMD 17), and Hospital Anxiety and Depression Scale (HADS). Cronbach’s alpha coefficient, test-retest reliability and confirmatory factor analysis were conducted. HADS and HAMD 17 were considered as the gold standard to investigate the criterion validity of the Chinese version of DARS. Results:The Cronbach’s α of the Chinese version of DARS was 0.97, the coefficient of the four domains ranged from 0.89 to 0.96. The intraclass correlation coefficient ( ICC) of test-retest reliability was 0.97， ICC of four domains ranged from 0.89 to 0.95 ( P<0.01)．The results of confirmation factor analysis of the Chinese version of DARS were as followed: χ 2/ df=2.02, GFI=0.88, RMSEA=0.08, CFI=0.96, and TLI=0.96. Validity: The total score and four domains of the Chinese version of DARS were significantly correlated with the seventh item of HAMD ( r=-0.38- -0.52, P<0.01) and all five items of HADS score ( r=-0.57- -0.75, P<0.01). There was significant difference between depression group and health control group. Conclusion:The Chinese version of DARS has good psychometric properties with adequate reliability and validity, and could be applied to assess the anhedonia of depression in China.

Epidemiological studies indicate that the use of antipsychotics in pregnant women has progressively increased. However, the safety evidence about antipsychotics use during pregnancy is scarce. The plausibility of antipsychotics use during pregnancy remains controversial. No antipsychotic has been approved for use during pregnancy by the National Medical Products Administration and Food and Drug Administration. Embryotoxicity of antipsychotics cannot be excluded. Currently, limited clinical and basic research evidence suggests that the use of antipsychotic drugs during pregnancy may have potential adverse effects on the long-term neurodevelopment of offspring.